<?xml version='1.0' encoding='iso-8859-1'?>
<newsitem date="1997-01-07" id="root" itemid="291450" xml:lang="en">
<title>USA: RESEARCH ALERT - Aviron started at buy.</title>
<headline>RESEARCH ALERT - Aviron started at buy.</headline>
<text>
<p>-- Robertson Stephens &amp; Co said analyst Ed Hurwitz has started coverage of Aviron Inc with a buy rating.</p>
<p>-- In a statement Hurwitz said Aviron, a drug development company focused on next-generation vaccine development, is working on live vaccines to prevent influenza, parainfluenza, cytomegalovirus infections, herpes simplex virus and respiratory syncycial virus.</p>
<p>-- The company's lead product, Cold Adapted Influenza Virus Vaccine (CAIV), is now in a 1,600-patient Phase III study with results expected in the second half of 1998. Hurwitz said the vaccine has a history of safety and efficacy.</p>
</text>
<copyright>(c) Reuters Limited 1997</copyright>
<metadata>
<dc element="dc.publisher" value="Reuters Holdings Plc" />
<dc element="dc.date.published" value="1997-01-07" />
<dc element="dc.source" value="Reuters" />
<dc element="dc.creator.location.country.name" value="USA" />
<dc element="dc.source" value="Reuters" />
</metadata>
</newsitem>